Last $62.22 USD
Change Today -0.02 / -0.03%
Volume 21.0K
As of 9:38 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Open
$62.23
Previous Close
$62.24
Day High
$62.42
Day Low
$62.14
52 Week High
11/11/13 - $64.10
52 Week Low
02/7/14 - $50.46
Market Cap
9.0B
Average Volume 10 Days
1.5M
EPS TTM
$3.90
Shares Outstanding
144.5M
EX-Date
07/7/14
P/E TM
16.0x
Dividend
$1.32
Dividend Yield
2.03%
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. It offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; and risk assessment services for the life insurance industry. The company also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, it provides molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the brand names of Atria and AlleleSeqr. Further, the company offers Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, including vital signs and progress notes; and ChartMaxx, an electronic document management system for hospitals. The company offers its diagnostic information services to patients, physicians, hospitals, integrated delivery networks, health plans, employers, and others through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

41,000 Employees
Last Reported Date: 02/18/14
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $472.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $573.9K
Senior Vice President of Clinical Franchises
Total Annual Compensation: $520.0K
Senior Vice President and General Counsel
Total Annual Compensation: $492.1K
Compensation as of Fiscal Year 2013.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Incorporated Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Earnings Guidance for the Year 2014

Quest Diagnostics Incorporated reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net revenues of $1,902 million compared to net revenues of $1,815 million for the same period a year ago. Operating income was $262 million compared to $289 million last year. Income from continuing operations before taxes was $229 million compared to $256 million last year. Income from continuing operations was $142 million compared to $161 million last year. Net income was $142 million compared to $174 million last year. Net income attributable to the company was $133 million compared to $165 million last year. Net income amounts attributable to the company common stockholders from income from continuing operations were $133 million or $0.92 per basic and diluted share compared to $152 million or $0.99 per basic and diluted share last year. Net income amounts attributable to the company common stockholders were $133 million or $0.92 per basic and diluted share compared to $165 million or $1.07 per basic and diluted share last year. Capital expenditures were $49 million in the second quarter of 2014. Adjusted operating income from continuing operations was $296 million, or 15.5% of revenues, compared to $308 million, or 16.9% of revenues, for 2013. Cash provided by operations was $280 million, compared to $208 million in the second quarter of 2013. Adjusted income from continuing operations was $157 million, or $1.08 per diluted share, compared to $164 million, or $1.06 per diluted share, for 2013. For the six months, the company reported net revenues of $3,648 million compared to net revenues of $3,602 million for the same period a year ago. Operating income was $470 million compared to $516 million last year. Income from continuing operations before taxes was $405 million compared to $453 million last year. Income from continuing operations was $253 million compared to $285 million last year. Net income was $253 million compared to $318 million last year. Net income attributable to the company was $237 million compared to $301 million last year. Net income amounts attributable to the company common stockholders from income from continuing operations were $237 million or $1.63 per diluted share compared to $268 million or $1.71 per diluted share last year. Net income amounts attributable to the company common stockholders were $237 million or $1.63 per diluted share compared to $301 million or $1.92 per diluted share last year. Net cash provided by operating activities was $364 million compared to $255 million last year. Capital expenditures were $117 million compared to $105 million last year. Adjusted income from continuing operations was $279 million, or $1.92 per diluted share, compared to $307 million, or $1.95 per diluted share, in 2013. Adjusted operating income from continuing operations for the first half of 2014 was $532 million, or 14.6% of revenues, compared to $579 million, or 16.1% of revenues, for 2013. For the year 2014, the company estimates results from continuing operations, before special items, as follows: Revenues expected to increase 2.5% to 3.5% compared to the prior year, versus previous guidance of up 2% to 4%; Adjusted diluted EPS to be between $4.00 and $4.10, versus previous guidance of between $3.95 and $4.15; Cash provided by operations to approximate $900 million, unchanged; and capital expenditures to approximate $300 million, unchanged.

Quest Diagnostics Adds Vicky Gregg to Board of Directors

Quest Diagnostics announced that its board of directors has elected Vicky Gregg to serve as a director, effective immediately, expanding the Board to 10 members. Ms. Gregg served as the Chief Executive Officer of Chattanooga-based Blue Cross Blue Shield of Tennessee from 2003 through December 2012. Prior to being elected CEO, she served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg is a noted national expert in health information technology and was appointed to the U.S. National Institutes of Health Commission on Systemic Interoperability in 2004.

Quest Diagnostics Announces Encouraging Data from Drug Abuse Study

Quest Diagnostics has announced data from a study which demonstrated decline in prescription drug misuse rates nationwide with multi-faceted drug abuse prevention programs. The findings suggest that broad, collaborative measures that include prescription drug databases and physician and patient education may be effective at curbing the nation's epidemic of prescription drug abuse. Florida, Georgia, Kentucky, New York and Tennessee showed the high rates of decline in misuse rates over the last three years, according to the study of more than 1.4 million drug test results between 2011 and 2013. The average decline for these states was 10.7%, nearly 2.5 times higher than the average decline of 4.4% for all other states combined, in the 46-state study. The Quest Diagnostics Health Trends study also found that 55% of Americans potentially put their health at risk by misusing their medications in 2013, a decrease of 8% points compared to misuse rates of 63% in 2011. All age groups and both genders were at risk of misuse, based on test results. The study's findings support previous research that suggests broad drug abuse approaches may be effective.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $62.22 USD -0.02

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $88.42 USD -0.56
Hologic Inc $26.00 USD +0.47
Laboratory Corp of America Holdings $105.69 USD +0.31
Myriad Genetics Inc $37.30 USD +0.25
QIAGEN NV €18.64 EUR +0.005
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 11.7x
Price/Sales 1.2x
Price/Book 2.2x
Price/Cash Flow 10.3x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.